Anti-tumor necrosis factor-alpha-induced psoriasis.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 16821276.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We describe a patient with rheumatoid arthritis who developed psoriasis during treatment with etanercept; psoriatic lesions resolved completely after the drug was discontinued, but returned on rechallenge. No such adverse skin reaction occurred after switching therapy to infliximab. Through a Medline search we identified 11 reports involving 32 patients who developed psoriasis/psoriasiform eruptions during therapy with tumor necrosis factor-alpha (TNF-alpha) inhibitors. All TNF-alpha blocking agents have been reported to lead to or exacerbate psoriasis. In some cases skin changes were severe enough to discontinue the medication.
Medical subject headings
- Antirheumatic Agents
- Arthritis, Rheumatoid
- Immunoglobulin G
- Psoriasis
- Tumor Necrosis Factor-alpha